Results 91 to 100 of about 5,005,064 (282)

Neuroimaging in pre-motor Parkinson's disease

open access: yesNeuroImage: Clinical, 2017
The process of neurodegeneration in Parkinson's disease begins long before the onset of clinical motor symptoms, resulting in substantial cell loss by the time a diagnosis can be made. The period between the onset of neurodegeneration and the development
Thomas R. Barber   +3 more
doaj   +1 more source

Resveratrol suppresses the growth and metastatic potential of cervical cancer by inhibiting STAT3Tyr705 phosphorylation

open access: yesCancer Medicine, 2020
Aberrant signal transducer and activator of transcription 3 (STAT3) signaling promotes the initiation and progression of cancer in humans by either inhibiting apoptosis or inducing cell proliferation, angiogenesis, invasion, and metastasis.
Xiaodong Sun   +9 more
doaj   +1 more source

Neurochemical Endpoints to Inform Early‐Stage Trials of Spinocerebellar Ataxia 2 and 3 in a Multisite Setting

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neurochemical levels measured by brain MR spectroscopy (MRS) have been proposed as endpoints for clinical trials in early‐stage spinocerebellar ataxia (SCA) trials. We tested their trial‐readiness by quantifying neurochemicals in three affected brain regions in early‐stage cohorts of SCA2 and SCA3, examining their reproducibility in ...
James M. Joers   +19 more
wiley   +1 more source

Models of probabilistic category learning in Parkinson's disease: Strategy use and the effects of L-dopa [PDF]

open access: yes, 2010
Probabilistic category learning (PCL) has become an increasingly popular paradigm to study the brain bases of learning and memory. It has been argued that PCL relies on procedural habit learning, which is impaired in Parkinson's disease (PD). However, as
Lagnado, DA   +4 more
core  

The effectiveness of traditional methods and altered auditory feedback in improving speech rate and intelligibility in speakers with Parkinson's disease [PDF]

open access: yes, 2010
Communication problems are a frequent symptom for people with Parkinson's disease (PD) which can have a significant impact on their quality-of-life. Deciding on the right management approach can be problematic though, as, with the exception of LSVT (R ...
Kröger, Bernd J.   +10 more
core   +1 more source

Founding Editorial: Neuro‐Drug Discovery

open access: yes
Neuro-Drug Discovery, EarlyView.
Wenbin Li
wiley   +1 more source

The Multiple Sclerosis Severity Allele rs10191329A and Cognitive Function: A UK Biobank Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The genome‐wide association study of Multiple Sclerosis severity linked the genetic variant rs10191329A to long‐term disability and implicated brain resilience as a determinant of outcome. We hypothesised that rs10191329A might influence cognition in other neurological diseases and healthy controls.
Ioanna Zimianiti   +5 more
wiley   +1 more source

Obstructive sleep apnea, periodic limb movements, and REM sleep without atonia are common in Parkinson's disease and correlate with motor symptom burden

open access: yesJournal of Parkinson’s Disease
Background Sleep disturbances are prevalent and debilitating non-motor symptoms in patients with Parkinson's disease (PD). Objective This study aimed to explore sleep architecture and the prevalence of polysomnographic (PSG) sleep findings in PD ...
Matteo Carpi   +10 more
doaj   +1 more source

Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease

open access: yesParkinson's Disease, 2010
Clinical trials have demonstrated positive proof of efficacy of dual metabotropic glutamate receptor 2/3 (mGluR2/3) agonists in both anxiety and schizophrenia.
Hugh Chan   +6 more
doaj   +1 more source

Parkinson’s Disease [PDF]

open access: yes, 2012
Parkinson's disease (PD) is the most common age-related motoric neurodegenerative disease initially described in the 1800's by James Parkinson as the 'Shaking Palsy'. Loss of the neurotransmitter dopamine was recognized as underlying the pathophysiology of the motor dysfunction; subsequently discovery of dopamine replacement therapies brought ...
Timothy R, Mhyre   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy